Therapy with mycophenolate mofetil for refractory acute and chronic graft-versus-host disease

We evaluated the pharmacokinetics and efficacy of oral mycophenolate mofetil (MMF) for treatment of refractory graft-versus-host disease (GVHD). In a prospective study of acute GVHD, 9 of 19 patients (47%) had a response and 10 (53%) had no improvement. Survival at 6 and 12 months after the start of...

Descripción completa

Detalles Bibliográficos
Autores principales: Furlong, Terry, Martin, Paul, Flowers, Mary E.D., Carnevale-Schianca, Fabrizio, Yatscoff, Randy, Chauncey, Thomas, Appelbaum, Frederick R., Deeg, H. Joachim, Doney, Kris, Witherspoon, Robert, Storer, Barry, Sullivan, Keith M., Storb, Rainer, Nash, Richard A.
Formato: Texto
Lenguaje:English
Publicado: 2009
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2791193/
https://www.ncbi.nlm.nih.gov/pubmed/19377515
http://dx.doi.org/10.1038/bmt.2009.76

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2791193/
https://www.ncbi.nlm.nih.gov/pubmed/19377515
http://dx.doi.org/10.1038/bmt.2009.76

Ejemplares similares